Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Benefits"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"CADTH Canadian Drug Expert Committee"
language:"English"
Showing
61
-
80
of
114
Search:
'"Benefits"'
,
query time: 0.01s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
61
CADTH Canadian Drug Expert Committee recommendation: Glecaprevir / Pibrentasvir (Maviret -- Abbvie Corporation) : indication : chronic hepatitis C virus infection
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
62
CDEC final recommendation: Dolutegravir (Tivicay -- ViiV Healthcare ULC) : indication : HIV infection
Published 2014
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
63
CADTH Canadian Drug Expert Committee final recommendation: Selexipag (Uptravi -- Actelion Pharmaceuticals Canada Inc.) : Indication: pulmonary arterial hypertension
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
64
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
65
CDEC final recommendation: Dolutegravir (Tivicay -- ViiV Healthcare ULC) : indication : HIV infection
Published 2014
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
66
CADTH Canadian drug expert committee recommendation: Doravirine (Pifeltro -- Merck Canada Inc.) : indication: in combination with other antiretroviral medicinal products, for the t...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
67
CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
68
CADTH Canadian Drug Expert Committee recommendation: Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
69
CADTH Canadian Drug Expert Committee recommendation: Dolutegravir/Lamivudine (Dovato -- ViiV healthcare ULC) : indication: as a complete regimen for the treatment of human immunode...
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
70
CADTH Canadian Drug Expert Committee recommendation: Glucagon nasal powder (Baqsimi -- Eli Lilly Canada Inc) : indication: for the treatment of severe hypoglycemia (SH) reactions w...
Published 2020
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
71
CADTH Canadian Drug Expert Committee recommendation: Teduglutide (Revestive -- Shire Pharmaceuticals Ireland Limited) : indication: treatment of adults and pediatric patients 1 yea...
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
72
CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
73
CADTH Canadian Drug Expert Committee Recommendation: Onabotulinumtoxin A (Botox -- Allergan Inc.) : indication: chronic migraine
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
74
CADTH Canadian drug expert committee recommendation (final): Certolizumab pegol (Cimzia -- UCB Canada Inc.) : indication : treatment of adult patients with moderate-to severe plaqu...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
75
CADTH Canadian drug expert committee recommendation: Doravirine (Pifeltro -- Merck Canada Inc.) : indication: in combination with other antiretroviral medicinal products, for the t...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
76
CADTH Canadian Drug Expert Committee recommendation: Migalastat (Galafold -- Amicus therapeutics) : indication : Fabry disease
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
77
CADTH Canadian drug expert committee recommendation: Telotristat ethyl (Xermelo -- Ipsen Biopharmaceuticals Canada Inc) : indication : for the treatment of refractory carcinoid syn...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
78
CADTH Canadian drug expert committee recommendation: Cysteamine ophthalmic solution (Cystadrops -- recordati rare diseases Canada Inc.) : indication : treatment of corneal cystine...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
79
CADTH Canadian Drug Expert Committee recommendation: Cerliponase Alfa (Brineura -- Biomarin Pharmaceutical [Canada] Inc.) : indication : for the treatment of neuronal ceroid lipofu...
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
80
CADTH Canadian Drug Expert Committee recommendation: Lixisenatide (Adlyxine -- Sanofi-Aventis Canada inc.) : indication : diabetes mellitus, type 2
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
1
2
3
4
5
6
Back
Narrow Search
Remove Filters
Clear Filter
Author: CADTH Canadian Drug Expert Committee
Clear Filter
Language: English
Year of Publication
From:
To:
Classification
610 - Medicine & health
110
330 - Economics
81
140 - Specific philosophical schools
11
700 - The arts; fine & decorative arts
8
800 - Literature & rhetoric
1
Language
English
Collection
National Center for Biotechnology Information
114
Author
CADTH Canadian Drug Expert Committee
Canadian Agency for Drugs and Technologies in Health
80
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?page=4&filter%5B%5D=author_facet%3A%22CADTH+Canadian+Drug+Expert+Committee%22&filter%5B%5D=language%3A%22English%22&lookfor=%22Benefits%22&type=Subject
Send by Email
×
Loading...